BioNTech Investor Day Presentation Deck
Diversified manufacturing expertise across four distinct capabilities.
Bulk mRNA
• End-to-end mRNA production capabilities
●
Combined >100,000 square ft across 2 facilities
Total capacity of >1 billion doses (COVID-19 vaccine)
Flexibility to support broad range of mRNA therapies
●
●
●
●
●
Marburg, Germany
New site, Singapore (planned for 2023)
Modular mRNA / BioNTainer
End-to-end mRNA production units with capacity of
up to 50 million doses/year
To initially support sustainable production of COVID-19
vaccines and Pandemic Preparedness offerings
Rwanda (under construction)
New sites, Senegal, South Africa (planned)
BioNTech
Manufacturing
Infrastructure
>1,000 employees
at 4 sites
●
●
Manufacturing and automation
Individualized mRNA
Semi-automated bespoke manufacturing capability to
produce just-in-time mRNA vaccines
>1,000 CGMP iNeST batches produced since 2018
Mainz, Germany (clinical)
New commercial site, Mainz (under construction)
Cell therapy
Two clinical-scale facilities with combined ~80,000 sq. ft
Deep expertise in gamma retroviral vectors and CAR-
T and TCR cell therapies
IMFS, Idar-Oberstein, Germany | Gaithersburg, MD, USA
BIONTECH
48View entire presentation